The NICE Guidelines published in 2015 state that testosterone supplementation can be considered for menopausal women with low sexual desire if hormone replacement therapy alone is not effective. There is however, no detail on what to prescribe, how much to prescribe or whether monitoring is required. At the time of conception of this project, there was no national guideline or official advice from the British Menopause Society. We decided to ask menopause experts from around the UK to see if a consensus could be reached about good prescribing practice. The method and results as discussed below may be helpful in future recommendations and guidance.
National Institute for Health and Care Excellence. Menopause: diagnosis and management, (NG23), NICE, www.nice.org.uk/guidance/ng23 (2015, accessed 20 August 2020).
2.
Hamoda H, Panay N, Pedder H, et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health 2020; 26(4): 181–209.
BachmannGBancroftJBraunsteinG, et al.
Female androgen insufficiency: the Princeton Consensus statement on definition, classification, and assessment. Fertility Sterility2002;
77: 660–665.
7.
Somboonporn W, Bell RJ and Davis SR. Testosterone for peri and postmenopausal women. Cochrane Database of Syst Reviews 2005; 4: Art. No. CD004509.
8.
GlaserRYorkAEDimitrakakisC.Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). Maturitas2011;
68: 355–361
9.
DavisSRMcCloudPStraussBJ, et al.
Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality.Maturitas2008;
61: 17–26.
10.
DavisonSLBellRJGavrilescuM, et al.
Testosterone improves verbal learning and memory in postmenopausal women: results from a pilot study. Maturitas2011;
70: 307–311.
11.
DavisSRDavisonSLGavrilescuM, et al.
Effects of testosterone on visuospatial function and verbal fluency in postmenopausal women: results from a functional magnetic resonance imaging pilot study. Menopause2014;
21: 410–414.
12.
DavisonSLBellRDonathS, et al.
Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab2005;
90: 3847–3853.
13.
DavisSRWahlin-JacobsenS.Testosterone in women – the clinical significance. Lancet Diabetes Endocrinol2015;
3: 980–992.
14.
BraunsteinGDReitzREBuchA, et al.
Testosterone reference ranges in normally cycling healthy premenopausal women. J Sex Med2011;
8: 2924–2934.
15.
BaberRJPanayNFentonA;
IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric2016;
19: 109–150.
16.
WiermanMEArltWBassonR, et al.
Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab2014;
99: 3489–3510.
17.
MaclaranKPanayN.The safety of postmenopausal testosterone therapy.Womens Health (Lond)2012;
8: 263–275.
18.
AchilliCPundirJRamanathanP, et al.
Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril2017;
107: 475–482.
19.
DavisSR.Cardiovascular and cancer safety of testosterone in women.Curr Opin Endocrinol Diabetes Obes2011;
18: 198–203.
20.
WorboysSKotsopoulosDTeedeH, et al.
Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab2001;
86: 158–161.
21.
IellamoFVolterraniMCaminitiG, et al.
Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol2010;
56: 1310–1316.
22.
KellyDMJonesTH.Testosterone: a metabolic hormone in health and disease. J Endocrinol2013;
217: R25–R45.
23.
van StaaTPSprafkaJM.Study of adverse outcomes in women using testosterone therapy. Maturitas2009;
62: 76–80.
24.
IslamRMBellRJGreenS, et al.
Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol2019;
7: 754–766.
25.
DimitrakakisCBondyC.Androgens and the breast. Breast Cancer Res2009;
11: 212.
26.
NachtigallLCassonPLucasJ, et al.
Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol2011;
27: 39–48.
27.
DavisSRMoreauMKrollR, et al.
APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med2008;
359: 2005–2017.
28.
PanayNAl-AzzawiFBouchardC, et al.
Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric2010;
13: 121–131.
29.
DavisSRWolfeRFarrugiaH, et al.
The incidence of invasive breast cancer among women prescribed testosterone for low libido. J Sex Med2009;
6: 1850–1856.
30.
GlaserRLDimitrakakisC.Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. Maturitas2013;
76: 342–349.
31.
GeraRTayehSChehadeHE, et al.
Does transdermal testosterone increase the risk of developing breast cancer? A systematic review. Anticancer Res2018;
38: 6615–6620.
32.
ChenRCuiJWangQ, et al.
Antiproliferative effects of anastrozole on MCF-7 human breast cancer cells in vitro are significantly enhanced by combined treatment with testosterone undecanoate. Mol Med Rep2015;
12: 769–775.
33.
GlaserRLYorkAEDimitrakakisC.Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications. Menopause2017;
24: 859–864.
34.
DahirMTravers-GustafsonD.Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy. Sex Med2014;
2: 8–15.
35.
WitherbySJohnsonJDemersL, et al.
Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist2011;
16: 424–431.
36.
BoniCPaganoMPanebiancoM, et al.
Therapeutic activity of testosterone in metastatic breast cancer.Anticancer Res2014;
34: 1287–1290.
37.
WhiteWBGradyDGiudiceLC, et al.
A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J2012;
163: 27–32.
ScottANewsonL.Should we be prescribing testosterone to perimenopausal and menopausal women? A guide to prescribing testosterone for women in primary care. Br J Gen Pract2020;
70: 203–204.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
